Josh Bilenker’s team at Eli Lil­ly chops 3 can­cer drug pro­grams in pipeline cleanup as their $1.6B IL-10 ef­fort flames out

Eli Lil­ly cut 3 ear­ly and mid-stage can­cer drug pro­grams from the pipeline to­day, 3 weeks af­ter the new on­col­o­gy team un­der Josh Bilenker nixed an al­liance it had un­der­way in the field with NextCure.

I’m still lin­ing up the drugs with the pro­gram, but the tar­gets make for an in­ter­est­ing list.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER